GoAI
Get started
Moolec Science S.A. logo

Moolec Science S.A.

MLEC

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$7.1288

+$0.1288 · +1.84%

Aug 24, 1:34 PM ET

MLEC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

79

Undervalued

Momentum

27

Weakening

Sentiment

40

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.

Industry
Biotechnology
Sector
Healthcare
Headquarters
KY
CEO
Alejandro Antalich
Listed since
Mar 2, 2021
Employees
103

Market position

Day range

Current $7.1288

52-week range

Current $7.1288

Open
$6.99
Previous close
$7.00
Volume
3.77K
0.17× average
Average volume
21.7K
Average daily volume
Market cap
5.18M USD
Beta
0.26
Market reference 1
50-day average
$7.3989
-3.65% below average
200-day average
$7.6296
-6.56% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
286.83M USD
EV / EBITDA
-4.16×
Earnings yield
-273.75%
Free cash flow yield
-73.93%

Profitability & efficiency

Return on equity
168.95%
Return on assets
-54.45%
Return on invested capital
-5.35%

Financial health

Current ratio
0.13×
Altman Z-score
-1.31
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends610%-1693%-3995%-6298%Gross margin, FY2022: -15.83%Gross margin, FY2023: 8.40%Gross margin, FY2024: 34.17%Operating margin, FY2022: -735.19%Operating margin, FY2023: -160.76%Operating margin, FY2024: -3.14%Net margin, FY2022: -5722.22%Net margin, FY2023: -129.99%Net margin, FY2024: -33.41%FY2020FY2021FY2022FY2023FY2024
Gross margin FY2022 -15.83%. Gross margin FY2023 8.40%. Gross margin FY2024 34.17%. Operating margin FY2022 -735.19%. Operating margin FY2023 -160.76%. Operating margin FY2024 -3.14%. Net margin FY2022 -5722.22%. Net margin FY2023 -129.99%. Net margin FY2024 -33.41%.

Income trends

Revenue

333.61M USD+5830.74%

Operating income

−10.48M USD-15.87%

Net income

−111.46M USD-1424.30%
Income trends across reported periods378.12M USD200.09M USD22.06M USD−155.97M USDRevenue, FY2022: 905.05K USDRevenue, FY2023: 5.63M USDRevenue, FY2024: 333.61M USDOperating income, FY2020: −13.8K USDOperating income, FY2021: −1.72M USDOperating income, FY2022: −6.65M USDOperating income, FY2023: −9.04M USDOperating income, FY2024: −10.48M USDNet income, FY2020: −13.8K USDNet income, FY2021: −4.53M USDNet income, FY2022: −51.79M USDNet income, FY2023: −7.31M USDNet income, FY2024: −111.46M USDFY2020FY2021FY2022FY2023FY2024
Revenue FY2022 905.05K USD. Revenue FY2023 5.63M USD. Revenue FY2024 333.61M USD. Operating income FY2020 −13.8K USD. Operating income FY2021 −1.72M USD. Operating income FY2022 −6.65M USD. Operating income FY2023 −9.04M USD. Operating income FY2024 −10.48M USD. Net income FY2020 −13.8K USD. Net income FY2021 −4.53M USD. Net income FY2022 −51.79M USD. Net income FY2023 −7.31M USD. Net income FY2024 −111.46M USD.
Metric (USD)FY2024FY2023FY2022FY2021FY2020
Revenue333.61M USD5.63M USD905.05K USD——
Cost of goods sold219.61M USD5.15M USD1.05M USD——
Gross profit114.01M USD472.58K USD−143.31K USD——
Research and development9.24M USD1.77M USD1.35M USD985.16K USD—
Selling, general, and administrative115.25M USD7.18M USD47.67M USD2.63M USD13.8K USD
Operating expenses124.48M USD9.52M USD6.51M USD3.65M USD13.8K USD
Interest income944.19K USD1.94M USD693.03K USD13.32K USD—
Interest expense41.81M USD1.17M USD160.04K USD2.13K USD—
Depreciation and amortization22.25M USD1.01M USD122.02K USD1.7K USD206.3K USD
Operating income−10.48M USD−9.04M USD−6.65M USD−1.72M USD−13.8K USD
Net income−111.46M USD−7.31M USD−51.79M USD−4.53M USD−13.8K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
50%
3 beats, 1 miss, 2 met estimates
Average EPS surprise
-2467.70%
6 comparable reports
Latest EPS result
-9
Estimate -9 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.06-5.98-11.9-17.81Q1 '24MetQ2 '24BeatQ4 '24MissQ1 '25BeatQ2 '25MetQ3 '25EstimateQ4 '25EstimateQ2 '26Estimate
Q1 2024, reported Mar 13, 2024: actual -7.5, estimate -7.5, surprise 0.00%, Met estimate. Q2 2024, reported May 30, 2024: actual -6, estimate -10.5, surprise +42.86%, Beat. Q4 2024, reported Oct 2, 2024: actual -10.49, estimate -0.07, surprise -14885.71%, Miss. Q1 2025, reported Jan 31, 2025: actual -7.5, estimate -9, surprise +16.67%, Beat. Q2 2025, reported Apr 16, 2025: actual -9, estimate -9, surprise 0.00%, Met estimate. Q3 2025, reported Jul 2, 2025: actual —, estimate -10.5, surprise —, Comparison unavailable. Q4 2025, reported Oct 27, 2025: actual —, estimate -0.7, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual —, estimate -16.5, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.7M3.27M1.83M393.55KQ1 '24MissQ2 '24BeatQ4 '24BeatQ1 '25BeatQ2 '25EstimateQ3 '25EstimateQ4 '25EstimateQ2 '26Estimate
Q1 2024, reported Mar 13, 2024: actual 463K USD, estimate 600K USD, surprise -22.83%, Miss. Q2 2024, reported May 30, 2024: actual 2.3M USD, estimate 650K USD, surprise +253.08%, Beat. Q4 2024, reported Oct 2, 2024: actual 1.62M USD, estimate 1.31M USD, surprise +23.99%, Beat. Q1 2025, reported Jan 31, 2025: actual 2.64M USD, estimate 1.32M USD, surprise +100.99%, Beat. Q2 2025, reported Apr 16, 2025: actual —, estimate 1.32M USD, surprise —, Comparison unavailable. Q3 2025, reported Jul 2, 2025: actual —, estimate 2.01M USD, surprise —, Comparison unavailable. Q4 2025, reported Oct 27, 2025: actual —, estimate 2.01M USD, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual —, estimate 4.39M USD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jan 5, 2026

1:15

Stock split

Effective May 14, 2025

1:10

MLEC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.91

+0.36%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.41

+0.20%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$549.02

+0.18%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.28

-0.67%

Sanofi logo

SNY

Sanofi

$45.63

-0.48%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$826.32

-0.93%

Continue in GoAI

Research MLEC

research.disclaimer